Back

Corrigendum to: Cardiovascular and kidney outcomes with finerenone in patients with type 2 diabetes and chronic kidney disease: the FIDELITY pooled analysis

European Heart Journal

12 January 2022
Organised by: Logo
Read full article
ESC Journals
You may be interested in
thumbnail
Congress Presentation
FIDELITY: Causes of mortality.
29 August 2022
thumbnail
Congress Presentation
Audience Q&A 
30 August 2025
thumbnail
Congress Presentation
Cardiovascular protection by combination of the selective nonsteroidal MR antagonist finerenone and the SGLT2 inhibitor empagliflozin in a preclinical model of hypertension-induced end-organ damage
27 August 2021
thumbnail
Congress Session
Does aldosterone synthase inhibition hold a key to transforming cardiorenal care?
19 May 2025

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources